Board Member
Rocket Pharmaceuticals, Inc. (RCKT)Equibles does not estimate personal net worth.
Get an email with a short summary when Rocket Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get RCKT alertsGaurav Shah is recorded as Board Member at Rocket Pharmaceuticals, Inc. (RCKT) since January 1, 2018 and CEO at Rocket Pharmaceuticals, Inc. (RCKT). The newest filing on record that lists Gaurav Shah as CEO and Board Member at Rocket Pharmaceuticals, Inc. (RCKT) is dated April 6, 2026. The proxy statement of Rocket Pharmaceuticals, Inc. reports total compensation of $3,510,241 for Gaurav Shah in fiscal 2025, including a base salary of $671,076. Disclosed compensation is on record for 8 fiscal years. Gaurav Shah has spoken on 1 earnings call and 4 other investor events across 1 company, most recently for Rocket Pharmaceuticals, Inc. on September 15, 2026. Rocket Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Rocket Pharmaceuticals, Inc. includes Aaron Ondrey (CFO), Carlos Garcia-Parada (CFO), John Militello (CFO) and 7 others.
“And if you have any questions, please reach out to your Morgan Stanley sales representative.”
“This is a very exciting year for Rocket Pharma. We are a gene therapy company. We are focused, laser focused, on cardiovascular genetic medicines, especially rare diseases where there's a high unmet need and where there are no alternative treatments other than heart transplant, which can be devastating in most cases.”
“We are a cardiac-focused genetic medicines company, primarily focused on genetic cardiomyopathies that while each one is a rare disease together, they're not rare.”
“Today marks an important milestone for Rocket Pharmaceuticals, and most importantly, for patients and families affected by severe leukocyte adhesion deficiency 1.”
“We have several updates to take you through. Let me highlight four key take-home points for today.”
2018-01-01–present
Last confirmed April 6, 2026
Start not stated–present
Last confirmed April 6, 2026
Biotechnology · Healthcare
CEO, Board Member
2018-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Rocket Pharmaceuticals, Inc. (RCKT) | Chief Executive Officer | $671,076 | $3,510,241 |
| 2024 | Rocket Pharmaceuticals, Inc. (RCKT) | Chief Executive Officer | $635,880 | $6,841,407 |
| 2023 | Rocket Pharmaceuticals, Inc. (RCKT) | Chief Executive Officer | $625,000 | $8,013,553 |
| 2022 | Rocket Pharmaceuticals, Inc. (RCKT) | Chief Executive Officer | $598,333 | $6,553,203 |
| 2021 | Rocket Pharmaceuticals, Inc. (RCKT) | Chief Executive Officer | $590,000 | $7,918,750 |
| 2020 | Rocket Pharmaceuticals, Inc. (RCKT) | Chief Executive Officer | $540,000 | $6,859,135 |
| 2019 | Rocket Pharmaceuticals, Inc. (RCKT) | Chief Executive Officer | $480,000 | $3,883,646 |
| 2018 | Rocket Pharmaceuticals, Inc. (RCKT) | M.D. Chief Executive Officer | $413,735 | $6,375,752 |
